Novo Nordisk said on Wednesday it will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. ...

Core Insights - Futures for major indexes, including the Dow Jones industrial average, rose slightly early Monday, indicating a positive market sentiment [1] - Alphabet (GOOGL) continues to experience a rally driven by its advancements in artificial intelligence [1] - Novo Nordisk (NVO) shares fell significantly after its Ozempic pill failed to demonstrate effectiveness in slowing Alzheimer's progression [1] - Eli Lilly (LLY) saw a slight decline, while Biogen (BIIB) experienced a notable increase in its stock price [1] Company Summaries - **Alphabet (GOOGL)**: The company is benefiting from its ongoing efforts in artificial intelligence, contributing to a rally in its stock price [1] - **Novo Nordisk (NVO)**: The company's stock tumbled due to disappointing results from its Ozempic pill in relation to Alzheimer's treatment [1] - **Eli Lilly (LLY)**: The stock edged lower, reflecting market reactions to recent developments [1] - **Biogen (BIIB)**: The company saw a jump in its stock price, indicating positive market sentiment or news [1]